

NCT ID	NCT05879822
Title	A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Phase	Phase 2
Date Added	2023-05-30
Location	Brazil China Georgia Greece Hungary New Zealand Romania South Africa Turkey
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	INCB099280
Tags	MSI-H/ MMRd
NCT ID	NCT05865535
Title	A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia
Phase	Phase 1
Date Added	2023-05-19
Location	California, United States Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05838768
Title	Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Phase	Phase 1
Date Added	2023-05-03

Location	California, United States
	Massachusetts, United States
	New York, United States
	Texas, United States
	Belgium
	China
	France
	Germany
	Israel
	Italy
	Japan
	Korea, Republic of
	Norway
	Singapore
	Spain
	Sweden
	Taiwan
	United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	HRO761, Irinotecan
Tags	MSI-H/ MMRd
<hr/>	
NCT ID	NCT05799443
Title	Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Phase	Phase 2
Date Added	2023-04-05
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	cetuximab, Irinotecan Hydrochloride, Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT05798533
Title	Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
Phase	Phase 1
Date Added	2023-04-04
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Cyclophosphamide, Fludarabine, Interleukin-2
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT05785325
Title	RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Phase	Phase 2
Date Added	2023-03-27
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting

Drugs	RC48-ADC plus Bevacizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05784688
Title	Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2023-03-27
Location	Texas, United States Washington, United States Korea, Republic of
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	TU2218 + Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT05783089
Title	MSLN-targeted CAR-T Cells in Solid Tumors.
Phase	Phase 1
Date Added	2023-03-24
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05771181
Title	Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Phase	Phase 2
Date Added	2023-03-16
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Fruquintinib, Tislelizumab, Vitamin E
Tags	MSS/ MMRp
NCT ID	NCT05770102
Title	DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Phase	Phase 2
Date Added	2023-03-15
Location	United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	Atezolizumab
Tags	MSI-H/ MMRd